DGAP-News

Carl Zeiss Meditec AG increases revenue to EUR 1,040 million / Market shares expanded in a number of markets

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Final Results
Carl Zeiss Meditec AG increases revenue to EUR 1,040 million / Market shares
expanded in a number of markets

16.12.2015 / 07:00
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------



Carl Zeiss Meditec AG increases revenue to EUR 1,040 million / Market
shares expanded in a number of markets

Medical technology company benefits from currency effects/Earnings impacted
by special effects

JENA, 16 December 2015
Carl Zeiss Meditec AG looks back on another positive fiscal year: boosted
by positive currency effects, the medical technology company's revenue
passed the billion mark in fiscal year 2014/15, with a 14 percent increase
to EUR 1,040 million. Adjusted for currency effects, this equates to growth
of around 8 percent over the prior year. Earnings before interest and taxes
(EBIT) increased by 8 percent, to EUR 130.6 million (prior year: EUR 120.7
million). The EBIT margin of 12.6 percent (prior year: 13.3 percent) was
impacted by additional strategic investments in research and development.
Adjusted for these additional investments, the EBIT margin would have been
at at 13.8 percent and thus at the same level as in the prior year - also
thanks to the positive currency effect on operating result (prior year:
13.7 percent). The Company's growth was attributable - to varying degrees -
to all three business units and global regions.

"A strong fourth quarter and tailwind from the exchange rates of major
currencies supported the good operating result. In contrast to the positive
currency effects on operating result, we had to accept charges from
currency hedging and write-downs in the financial result," says Dr. Ludwin
Monz, President and CEO of Carl Zeiss Meditec AG.

Key figures by business unit at a glance

Once again, the strategic business unit (SBU) Surgical Ophthalmology
achieved the strongest growth in the fiscal year. Revenue increased by 22.5
percent (adjusted for currency effects 19.0 percent), to EUR 355.3 million
(prior year: EUR 290.0 million). Business was driven both by good demand
for intraocular lenses and consumables for cataract surgery and for
surgical workstations for ophthalmology.

Revenue of the Ophthalmic Systems SBU increased by 12.2 percent (adjusted
for currency effects, 3.9 percent), to EUR 392.0 million (prior year: EUR
349.3 million). As in the previous quarters, the area of diagnostics
suffered from price and competitive pressure, while the refractive laser